Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHRH1SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASLC6A2
The experimentally established mechanism targets of Orphenadrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.94 |
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.94 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.94 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.94 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.94 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.94 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.94 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.94 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.94 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.69 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.69 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.69 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.94 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.94 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.94 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.94 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.94 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orphenadrine SCHEMBL28727 | 0.97 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Orphenadrine SCHEMBL29359844 | 0.97 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Orphenadrine SCHEMBL119471 | 0.97 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Orphenadrine SCHEMBL30903909 | 0.95 | LMNA (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Orphenadrine SCHEMBL1235378 | 0.95 | LMNA (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Hydrochloric Acid SCHEMBL29519368 | 0.87 | LMNA (0.84) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| Diphenhydramine SCHEMBL3008185 | 0.86 | SLC6A2 (0.93) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| SCHEMBL2615259 | 0.86 | SLC6A2 (0.79) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| SCHEMBL637495 | 0.85 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 | |
| SCHEMBL4667597 | 0.84 | CYP2D6 (0.76) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4724114-A1 | CYANOACRYLATE ADHESIVE KITS | Chemence, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2026041855-A1 | CYANOACRYLATE ADHESIVE KITS | CHEMENCE, INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| US-20220273637-A1 | NOVEL PFAR-INHIBITING COMPOUNDS | Institut National de la Santé et de la Recherche Médicale (FR) | 2022-09-01 | — | — | US | disclosed |
| US-20220031719-A1 | ANTIVIRAL THERAPEUTIC DRUG COMBINATIONS | THE UNIVERSITY OF TULSA (US) | 2022-02-03 | — | — | US | disclosed |
| EP-2554184-B1 | PREVENTIVE AND/OR REMEDY FOR HAND AND FOOT SYNDROME | ONO PHARMACEUTICAL CO (JP) | 2016-10-26 | — | — | EP | disclosed |
| US-8729056-B2 | Preventive and/or therapeutic agent of hand-foot syndrome | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20130045956-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT OF HAND-FOOT SYNDROME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-02-21 | — | — | US | disclosed |
| EP-2554184-A1 | PREVENTIVE AND/OR REMEDY FOR HAND AND FOOT SYNDROME | ONO Pharmaceutical Co., Ltd. (JP) | 2013-02-06 | — | — | EP | disclosed |
| EP-2021502-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | Oy Jurilab Ltd (FI) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007128884-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | OY JURILAB LTD (FI) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031719-A1 | ANTIVIRAL THERAPEUTIC DRUG COMBINATIONS | HK2, G6PD, GCK | SLC6A2 1798/4885HRH1 3305/4885GRIN2D 425/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | SLC6A2 804/4885HRH1 1245/4885GRIN2D 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.